Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment

We identified resistance mechanisms to abiraterone acetate/prednisone (AA/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study. We analyzed whole-exome sequencing (WES) and RNA-sequencing data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sicotte, Hugues, Kalari, Krishna R., Qin, Sisi, Dehm, Scott M., Bhargava, Vipul, Gormley, Michael, Tan, Winston, Sinnwell, Jason P., Hillman, David W., Li, Ying, Vedell, Peter T., Carlson, Rachel E., Bryce, Alan H., Jimenez, Raphael E., Weinshilboum, Richard M., Kohli, Manish, Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Cancer Genes and Networks
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716248/
https://www.ncbi.nlm.nih.gov/pubmed/36135372
http://dx.doi.org/10.1158/1541-7786.MCR-22-0099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716248/
https://www.ncbi.nlm.nih.gov/pubmed/36135372
http://dx.doi.org/10.1158/1541-7786.MCR-22-0099

Ejemplares similares